Ciprofloxacin (Cipro)

Category:

  • Antibiotic

Description:

  • Fluoroquinolone antibiotic

Indications:

  • Lower respiratory tract infections (E. coli, Klebsiella pneumonia, Enterobacter cloacae, P. mirabilis, P. aeruginosa, H. influenzae, H. parainfluenzae, S. pneumoniae)

  • Skin infections (E. coli, K. pneumoniae, E. cloacae, P. mirabilis, P. vulgaris, Providencia stuartii, M. morganii, Citrobacter freundii, S. pyogenes, P. aeruginosa, S. aureus, S. epidermidis)

  • Bone/joint infections (E. cloacae, Serratia marcescens, P. aeruginosa)

  • Urinary tract infections (E. coli, K. pneumoniae, E. cloacae, S. marcescens, P. mirabilis, Providencia rettgeri, M. morganii, Citrobacter diversus, C. freundii, P. aeruginosa, S. eipdermidis, Entercoccus faecalis)

  • Infectious diarrhea (E. coli, Campylobacter jejuni, Shigells flexneri, Shigella sonnei)

  • Typhoid fever (Salmonella typhi)

  • Sexually transmitted diseases (N. gonorrhoeae)

  • Anthrax treatment and exposure prophylaxis

  • Unlabeled uses:

  • cystic fibrosis

  • malignant external otitis

  • tuberculosis

  • Mycobaterium avium complex infection in AIDS patients

Contraindications:

  • None

Precautions:

  • Pregnancy category C

  • May cause photosensitivity reactions

  • May cause pseudomembranous colitis

  • Do not use in young children due to possible cartilage abnormalities

  • May cause ophthalmologic abnormalities

  • Administer on an empty stomach

  • Do not take with antacids, iron, aluminum, magnesium or zinc preparations, milk or dairy products

  • May cause dizziness or lightheadedness, use caution when performing tasks

  • Take each dose with a full glass of water

  • Take on empty stomach, food delays absorption.  Optimal dosing is 2 hours after eating

  • Complete full course of therapy

Adverse Reactions (Side Effects):

  • Angina pectoris, bronchospasm, dyspnea

  • Bad taste in mouth

  • Mental confusion, restlessness

 

Dosage:

  • Administered orally (capsules and suspension) and by IV injection

  • UTIs (mild/moderate): 

    • 250mg po q12h or 200mg IV q12h

  • UTIs (serious/complicated): 

    • 500mg po q12h or 400mg IV q12h

  • Lower resp, skin, bone or joint infection (mild/moderate): 

    • 500mg po q12h or 400mg IV q12h

  • Lower resp, skin, bone or joint infection (serious/complicate): 

    • 750mg po q12h or 400mg IV q8h

  • Infectious diarrhea: 

    • 500mg po q12h

  • Typhoid fever: 

    • 500mg po q12h

  • Urethral/Cervical gonococcal infections (uncomplicated): 

    • 250-500mg single dose

  • Chancroid: 

    • 500mg q12h for 3 days

  • Disseminated gonococcal infections: 

    • 500mg q12h for 7 days following initial treatment with ceftriaxone (1 gram IM or IV q24h until 24-48 after improvement)

  • Anthrax:

    • 1200-2400mg/day with pyrimethamine

    • treatment: 

      • Adult: 400mg IV q12h

      • Child: 2-30mg/kg/day in 2 divided doses

    • prophylaxis: 

      • Adult: 500mg po bid

      • Child: 20-30mg/kg/day divided q12h

 

Home  ·  Military Medicine  ·  Sick Call  ·  Basic Exams  ·  Medical Procedures  ·  Lab and X-ray  ·  The Pharmacy  ·  The Library  ·  Equipment  ·  Patient Transport  ·  Medical Force Protection  ·  Operational Safety  ·  Operational Settings  ·  Special Operations  ·  Humanitarian Missions  ·  Instructions/Orders  ·  Other Agencies  ·  Video Gallery  ·  Forms  ·  Web Links  ·  Acknowledgements  ·  Help  ·  Feedback

Approved for public release; Distribution is unlimited.

The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks.

Source: Operational Medicine 2001, Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300.

Bureau of Medicine and Surgery
Department of the Navy
2300 E Street NW
Washington, D.C
20372-5300

Operational Medicine
 Health Care in Military Settings
CAPT Michael John Hughey, MC, USNR
NAVMED P-5139
  January 1, 2001

United States Special Operations Command
7701 Tampa Point Blvd.
MacDill AFB, Florida
33621-5323

*This web version is provided by The Brookside Associates, LLC.  It contains original contents from the official US Navy NAVMED P-5139, but has been reformatted for web access and includes advertising and links that were not present in the original version. The medical information presented was reviewed and felt to be accurate in 2001. Medical knowledge and practice methods may have changed since that time. Some links may no longer be active. This web version has not been approved by the Department of the Navy or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. The Brookside Associates is a private organization, not affiliated with the United States Department of Defense.

© 2015, Brookside Associates, LLC. All rights reserved

Other Brookside Products

 

 

Advertise on this site